BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 556 filers reported holding BIO-TECHNE CORP in Q3 2021. The put-call ratio across all filers is 1.21 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $5,095,038 | -14.4% | 74,850 | +2.7% | 0.04% | -11.1% |
Q2 2023 | $5,952,051 | +8.6% | 72,915 | -1.3% | 0.04% | +4.7% |
Q1 2023 | $5,480,117 | -1.2% | 73,866 | +10.4% | 0.04% | -4.4% |
Q4 2022 | $5,546,991 | +11.7% | 66,928 | +282.7% | 0.04% | +4.7% |
Q3 2022 | $4,967,000 | -8.3% | 17,487 | +11.8% | 0.04% | -2.3% |
Q2 2022 | $5,419,000 | -16.2% | 15,637 | +4.7% | 0.04% | 0.0% |
Q1 2022 | $6,469,000 | -14.5% | 14,939 | +2.1% | 0.04% | -10.2% |
Q4 2021 | $7,566,000 | +2.1% | 14,625 | -4.4% | 0.05% | -5.8% |
Q3 2021 | $7,411,000 | +0.7% | 15,295 | -6.4% | 0.05% | 0.0% |
Q2 2021 | $7,361,000 | +10.1% | 16,349 | -6.6% | 0.05% | +2.0% |
Q1 2021 | $6,683,000 | +14.2% | 17,498 | -5.0% | 0.05% | +8.5% |
Q4 2020 | $5,850,000 | +14.4% | 18,421 | -10.8% | 0.05% | +2.2% |
Q3 2020 | $5,113,000 | +5.7% | 20,644 | +12.8% | 0.05% | -2.1% |
Q2 2020 | $4,835,000 | +42.7% | 18,308 | +2.5% | 0.05% | +14.6% |
Q1 2020 | $3,388,000 | -11.4% | 17,864 | +2.6% | 0.04% | +13.9% |
Q4 2019 | $3,822,000 | +7.8% | 17,411 | -3.9% | 0.04% | 0.0% |
Q3 2019 | $3,544,000 | +228.5% | 18,114 | +249.9% | 0.04% | +200.0% |
Q2 2019 | $1,079,000 | +16.6% | 5,177 | +11.1% | 0.01% | +9.1% |
Q1 2019 | $925,000 | -38.5% | 4,660 | -55.2% | 0.01% | -42.1% |
Q4 2018 | $1,505,000 | -28.6% | 10,405 | +0.7% | 0.02% | -24.0% |
Q3 2018 | $2,108,000 | +22.8% | 10,330 | -10.9% | 0.02% | +13.6% |
Q2 2018 | $1,717,000 | -55.3% | 11,600 | -54.4% | 0.02% | -12.0% |
Q1 2018 | $3,842,000 | +165.9% | 25,440 | +128.2% | 0.02% | +31.6% |
Q4 2017 | $1,445,000 | +6.6% | 11,150 | -0.5% | 0.02% | +5.6% |
Q3 2017 | $1,355,000 | +5.2% | 11,205 | +2.2% | 0.02% | 0.0% |
Q2 2017 | $1,288,000 | +41.4% | 10,965 | +22.3% | 0.02% | +38.5% |
Q1 2017 | $911,000 | +9.8% | 8,965 | +11.0% | 0.01% | +8.3% |
Q4 2016 | $830,000 | -9.3% | 8,080 | -3.3% | 0.01% | -14.3% |
Q3 2016 | $915,000 | -9.8% | 8,355 | -7.1% | 0.01% | -12.5% |
Q2 2016 | $1,014,000 | +7.2% | 8,995 | -10.2% | 0.02% | 0.0% |
Q1 2016 | $946,000 | +3.3% | 10,015 | -1.6% | 0.02% | +6.7% |
Q4 2015 | $916,000 | +9.0% | 10,183 | +12.1% | 0.02% | +7.1% |
Q3 2015 | $840,000 | -10.1% | 9,083 | -4.2% | 0.01% | -6.7% |
Q2 2015 | $934,000 | -12.9% | 9,483 | -11.2% | 0.02% | -11.8% |
Q1 2015 | $1,072,000 | +8.6% | 10,683 | 0.0% | 0.02% | +6.2% |
Q4 2014 | $987,000 | – | 10,683 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |